Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Duloxetine’s Dual Names: Lilly Wants Yentreve As Incontinence Brand

Executive Summary

Lilly is asking FDA to accept Yentreve as the trade name for duloxetine for the treatment of stress urinary incontinence

You may also be interested in...



Lilly GMPs Clear One Milestone; Cymbalta Launch Now Planned For Summer

Lilly plans to launch Cymbalta in summer 2004, pending a pre-approval inspection and the build-up of sufficient product inventory

Lilly GMPs Clear One Milestone; Cymbalta Launch Now Planned For Summer

Lilly plans to launch Cymbalta in summer 2004, pending a pre-approval inspection and the build-up of sufficient product inventory

Lilly Cymbalta Approval Timeline In Doubt After Delay In Second NDA

Lilly's plans to launch Cymbalta at the start of 2004 appear to hinge on the company's ability to convince FDA that the drug interaction issues delaying approval of duloxetine for incontinence should not hold up availability of the drug for depression

Related Content

UsernamePublicRestriction

Register

PS042682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel